Impact of extratumoral lymphatic permeation on postoperative survival of non-small-cell lung cancer patients

Yuki Matsumura, Tomoyuki Hishida, Yoshihisa Shimada, Genichiro Ishii, Keiju Aokage, Junji Yoshida, Kanji Nagai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

INTRODUCTION: Lymphatic permeation has been reported as a prognostic factor for patients with resected non-small-cell lung cancer (NSCLC). Lymphatic canals are located in both intratumoral and extratumoral areas. Since 2001, we have prospectively evaluated lymphatic permeation based on its location. The purpose of this study was to determine the survival impact of extratumoral lymphatic permeation in patients with resected NSCLC by analyzing the long-term follow-up data. METHODS: We reviewed 1069 consecutive patients with NSCLC who underwent complete resection between 2001 and 2006. Lymphatic permeation was classified as follows: ly0, absence of lymphatic permeation; ly1, intratumoral; and ly2, extratumoral. RESULTS: There were 845 patients (79%) with ly0, 134 (12%) with ly1, and 90 (9%) with ly2. Ly2 was more frequently observed in patients with advanced disease and intrapulmonary metastases than ly0-1. The 5-year overall survival (OS) rates of the ly0, ly1, and ly2 groups were 75%, 63%, and 34%, respectively. The OS rate was significantly worse in the ly2 group compared with OS rate in the ly0 (p < 0.01) and ly1 groups (p < 0.01). In multivariate analyses, ly2 proved to be an independent poor prognostic factor (hazard ratio, 1.73; p < 0.01). OS and recurrence-free survival of patients with T1 and T2 tumors with ly2 were not statistically different from that of the patients with T3 tumor (OS, p = 0.43 and p = 0.77; recurrence-free survival, p = 0.94 and p = 0.94, respectively). CONCLUSIONS: The adverse prognostic impact of lymphatic permeation was remarkably different whether it is detected in intratumoral or extratumoral lymphatic canals. We recommend that lymphatic permeation in resected NSCLC should be evaluated by considering its location.

Original languageEnglish
Pages (from-to)337-344
Number of pages8
JournalJournal of Thoracic Oncology
Volume9
Issue number3
DOIs
Publication statusPublished - 2014 Mar
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Survival Rate
Recurrence
Neoplasms
Multivariate Analysis
Neoplasm Metastasis

Keywords

  • Lymphatic permeation
  • Non-small-cell lung cancer
  • Prognostic factor
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Impact of extratumoral lymphatic permeation on postoperative survival of non-small-cell lung cancer patients. / Matsumura, Yuki; Hishida, Tomoyuki; Shimada, Yoshihisa; Ishii, Genichiro; Aokage, Keiju; Yoshida, Junji; Nagai, Kanji.

In: Journal of Thoracic Oncology, Vol. 9, No. 3, 03.2014, p. 337-344.

Research output: Contribution to journalArticle

Matsumura, Yuki ; Hishida, Tomoyuki ; Shimada, Yoshihisa ; Ishii, Genichiro ; Aokage, Keiju ; Yoshida, Junji ; Nagai, Kanji. / Impact of extratumoral lymphatic permeation on postoperative survival of non-small-cell lung cancer patients. In: Journal of Thoracic Oncology. 2014 ; Vol. 9, No. 3. pp. 337-344.
@article{170607e74a9f42d3aacc5e4cb575de01,
title = "Impact of extratumoral lymphatic permeation on postoperative survival of non-small-cell lung cancer patients",
abstract = "INTRODUCTION: Lymphatic permeation has been reported as a prognostic factor for patients with resected non-small-cell lung cancer (NSCLC). Lymphatic canals are located in both intratumoral and extratumoral areas. Since 2001, we have prospectively evaluated lymphatic permeation based on its location. The purpose of this study was to determine the survival impact of extratumoral lymphatic permeation in patients with resected NSCLC by analyzing the long-term follow-up data. METHODS: We reviewed 1069 consecutive patients with NSCLC who underwent complete resection between 2001 and 2006. Lymphatic permeation was classified as follows: ly0, absence of lymphatic permeation; ly1, intratumoral; and ly2, extratumoral. RESULTS: There were 845 patients (79{\%}) with ly0, 134 (12{\%}) with ly1, and 90 (9{\%}) with ly2. Ly2 was more frequently observed in patients with advanced disease and intrapulmonary metastases than ly0-1. The 5-year overall survival (OS) rates of the ly0, ly1, and ly2 groups were 75{\%}, 63{\%}, and 34{\%}, respectively. The OS rate was significantly worse in the ly2 group compared with OS rate in the ly0 (p < 0.01) and ly1 groups (p < 0.01). In multivariate analyses, ly2 proved to be an independent poor prognostic factor (hazard ratio, 1.73; p < 0.01). OS and recurrence-free survival of patients with T1 and T2 tumors with ly2 were not statistically different from that of the patients with T3 tumor (OS, p = 0.43 and p = 0.77; recurrence-free survival, p = 0.94 and p = 0.94, respectively). CONCLUSIONS: The adverse prognostic impact of lymphatic permeation was remarkably different whether it is detected in intratumoral or extratumoral lymphatic canals. We recommend that lymphatic permeation in resected NSCLC should be evaluated by considering its location.",
keywords = "Lymphatic permeation, Non-small-cell lung cancer, Prognostic factor, Surgery",
author = "Yuki Matsumura and Tomoyuki Hishida and Yoshihisa Shimada and Genichiro Ishii and Keiju Aokage and Junji Yoshida and Kanji Nagai",
year = "2014",
month = "3",
doi = "10.1097/JTO.0000000000000073",
language = "English",
volume = "9",
pages = "337--344",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

TY - JOUR

T1 - Impact of extratumoral lymphatic permeation on postoperative survival of non-small-cell lung cancer patients

AU - Matsumura, Yuki

AU - Hishida, Tomoyuki

AU - Shimada, Yoshihisa

AU - Ishii, Genichiro

AU - Aokage, Keiju

AU - Yoshida, Junji

AU - Nagai, Kanji

PY - 2014/3

Y1 - 2014/3

N2 - INTRODUCTION: Lymphatic permeation has been reported as a prognostic factor for patients with resected non-small-cell lung cancer (NSCLC). Lymphatic canals are located in both intratumoral and extratumoral areas. Since 2001, we have prospectively evaluated lymphatic permeation based on its location. The purpose of this study was to determine the survival impact of extratumoral lymphatic permeation in patients with resected NSCLC by analyzing the long-term follow-up data. METHODS: We reviewed 1069 consecutive patients with NSCLC who underwent complete resection between 2001 and 2006. Lymphatic permeation was classified as follows: ly0, absence of lymphatic permeation; ly1, intratumoral; and ly2, extratumoral. RESULTS: There were 845 patients (79%) with ly0, 134 (12%) with ly1, and 90 (9%) with ly2. Ly2 was more frequently observed in patients with advanced disease and intrapulmonary metastases than ly0-1. The 5-year overall survival (OS) rates of the ly0, ly1, and ly2 groups were 75%, 63%, and 34%, respectively. The OS rate was significantly worse in the ly2 group compared with OS rate in the ly0 (p < 0.01) and ly1 groups (p < 0.01). In multivariate analyses, ly2 proved to be an independent poor prognostic factor (hazard ratio, 1.73; p < 0.01). OS and recurrence-free survival of patients with T1 and T2 tumors with ly2 were not statistically different from that of the patients with T3 tumor (OS, p = 0.43 and p = 0.77; recurrence-free survival, p = 0.94 and p = 0.94, respectively). CONCLUSIONS: The adverse prognostic impact of lymphatic permeation was remarkably different whether it is detected in intratumoral or extratumoral lymphatic canals. We recommend that lymphatic permeation in resected NSCLC should be evaluated by considering its location.

AB - INTRODUCTION: Lymphatic permeation has been reported as a prognostic factor for patients with resected non-small-cell lung cancer (NSCLC). Lymphatic canals are located in both intratumoral and extratumoral areas. Since 2001, we have prospectively evaluated lymphatic permeation based on its location. The purpose of this study was to determine the survival impact of extratumoral lymphatic permeation in patients with resected NSCLC by analyzing the long-term follow-up data. METHODS: We reviewed 1069 consecutive patients with NSCLC who underwent complete resection between 2001 and 2006. Lymphatic permeation was classified as follows: ly0, absence of lymphatic permeation; ly1, intratumoral; and ly2, extratumoral. RESULTS: There were 845 patients (79%) with ly0, 134 (12%) with ly1, and 90 (9%) with ly2. Ly2 was more frequently observed in patients with advanced disease and intrapulmonary metastases than ly0-1. The 5-year overall survival (OS) rates of the ly0, ly1, and ly2 groups were 75%, 63%, and 34%, respectively. The OS rate was significantly worse in the ly2 group compared with OS rate in the ly0 (p < 0.01) and ly1 groups (p < 0.01). In multivariate analyses, ly2 proved to be an independent poor prognostic factor (hazard ratio, 1.73; p < 0.01). OS and recurrence-free survival of patients with T1 and T2 tumors with ly2 were not statistically different from that of the patients with T3 tumor (OS, p = 0.43 and p = 0.77; recurrence-free survival, p = 0.94 and p = 0.94, respectively). CONCLUSIONS: The adverse prognostic impact of lymphatic permeation was remarkably different whether it is detected in intratumoral or extratumoral lymphatic canals. We recommend that lymphatic permeation in resected NSCLC should be evaluated by considering its location.

KW - Lymphatic permeation

KW - Non-small-cell lung cancer

KW - Prognostic factor

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84894517502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894517502&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000073

DO - 10.1097/JTO.0000000000000073

M3 - Article

C2 - 24496002

AN - SCOPUS:84894517502

VL - 9

SP - 337

EP - 344

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -